Phase II study of first-line WHIT panitumumab and capecitabine in elderly patients with metastatic colorectal cancer and wild type KRAS

Trial Profile

Phase II study of first-line WHIT panitumumab and capecitabine in elderly patients with metastatic colorectal cancer and wild type KRAS

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Capecitabine (Primary) ; Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Sep 2017 Status changed from recruiting to completed.
    • 12 Sep 2017 Preliminary results presented at the 42nd European Society for Medical Oncology Congress.
    • 06 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top